APOE and Alzheimer disease: Further studies in larger cohorts are required to validate the utility of GPC2 as an AD biomarker, and to investigate if an interaction with APOE exits in vivo, since the 34-kD glycoprotein exerts its function in lipoprotein clearance via binding to specific cell surface receptors, including the LDL receptor and diverse HSPGs.